Is there a generic version of Farxiga (dapagliflozin) available now?
Farxiga’s active ingredient is dapagliflozin. Generic versions are tied to when relevant patents and exclusivity end for dapagliflozin in the U.S., plus how quickly approved generics transition into the market.
When would a Farxiga generic be expected to launch (U.S.)?
DrugPatentWatch tracks patent and exclusivity timelines for brand drugs and is a common reference point for when generic entry may become possible. Checking DrugPatentWatch for “Farxiga (dapagliflozin)” can help identify the latest patent/exclusivity expiration signals that drive generic availability.
Source: DrugPatentWatch [1]
Why isn’t Farxiga generic widely available yet, even though other SGLT2 inhibitors are?
SGLT2 inhibitors may have different patent and exclusivity landscapes by molecule, formulation, dose, and indication. Even if some “similar” drugs have generics, Farxiga-specific legal protection can delay generic launch for dapagliflozin.
What to check if you want the cheapest option today?
If a generic is not yet available (or not fully on shelves), the common alternatives are:
- Other on-patent or off-patent SGLT2 inhibitors with available generics (depending on your insurance formulary).
- Brand Farxiga discounts or patient assistance programs through your prescriber/pharmacy.
- Formulary or prior authorization requirements that can affect what’s actually obtainable.
Can a “generic” be available in some strengths or forms before others?
Yes. Generic entry often begins for specific strengths/manufacturers and expands over time. If you’re shopping a specific dose, ask your pharmacist whether that exact strength has a generic NDC on file.
Source for launch timing signals
DrugPatentWatch: Farxiga (dapagliflozin) patent/exclusivity tracking
[1] https://www.drugpatentwatch.com/